BioAtla Presented Data Characterizing Mutated KRAS Genotype And Clinical Outcomes In Patients With Advanced NSCLC Treated With Mecbotamab Vedotin, A CAB-AXL-ADC, At The IASLC 2024; 1-Year OS Was 58% For Patients With NSCLC Expressing MKRAS Versus 23% For WtKRAS

Improved median overall survival (OS) for Mec-V treated patients with treatment-refractory non-small cell lung cancer (NSCLC) expressing mutated KRAS (mKRAS) as compared to Mec-V treated patient with treatment-refractory NSCLC expressing wild-type KRAS (wtKRAS)

One-year OS was 58% for patients with NSCLC expressing mKRAS versus 23% for wtKRAS

Mec-V antitumor activity observed across 9 different mKRAS variants

Strong association of AXL expression by mKRAS NSCLC confirmed

SAN DIEGO, Dec. 16, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, presented a poster entitled "Characterization of Mutated KRAS Genotype and Clinical Outcomes in Patients With Advanced NSCLC Treated With Mecbotamab Vedotin, a CAB-AXL-ADC" at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting on December 14, 2024.